Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases

Hongyu Xu1
Lin Zhou2
You Lu2
Xiaomei Su1
Peng Cheng1
Dong Li1
Hui Gao1
Hua Li1
Weiwei Yuan1
Ling Zhang1
Ta Zhao1

1Department of Oncology, The General Hospital of Western Theater Command, Chengdu, People’s Republic of China; 2Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

Abstract: Leptomeningeal metastases (LM) occur in 3–5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.

Keywords: leptomeningeal metastases, non-small cell lung cancer, nimotuzumab, erlotinib

Introduction

Leptomeningeal metastases (LM) occur in 3–5% of patients with non-small-cell lung cancer (NSCLC) and are a detrimental complication associated with poor prognosis.1,2 Patients with LM are usually unable to accept systematic chemotherapy and present devastating headache. Whole brain radiotherapy (WBRT) remains controversial, some authors claim that it predicts favorable survival, but others proclaim its severe side effects accelerate patients’ death.3,4 Therefore, optimal therapeutic approaches are a big challenge. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is proved to be effective for patients with EGFR sensitive mutations in NSCLC in recent years.1,5,6 Some authors have reported that the incidence of harboring EGFR sensitive mutations for patients with LM is 58.1%.7 Erlotinib is more widely used to treat patients with central nervous system (CNS) metastases including LM because of its better penetration of brain-blood barriers (BBB) than gefitinib and icotinib.8,9 Nevertheless, the concentration in cerebrospinal fluid (CSF) is much lower than that in blood.10 Consequently, there are emerging reports indicating high-dose EGFR-TKI could increase the concentration in CSF for EGFR=mutated patients with LM, especially in patients’ CNS progression after taking standard-dose EGFR-TKI.11,12 High-dosage erlotinib did improve the control rate of LM, but it was associated with
Osimertinib, the third-generation TKI, found the disease control rate (DCR) was 91.6%. However, the application of nimotuzumab combined with whole brain radiotherapy can reach to 91.6%. However, the application of nimotuzumab in LM has been rarely reported. Therefore, the aim of study was to research dual targeting of the epidermal growth factor receptor using combination of nimotuzumab and erlotinib in advanced NSCLC with LM to provide ideas for clinical practice.

Case 1
A 45-year-old female, was diagnosed with lung stage IV adenocarcinoma in 2014, with primary tumors of 2 cm in the upper left lobe, liver, bone and left eye metastases. Demographic profiles of this case are listed in Table 1. She started to take gefitinib (250 mg/ctuximab) orally with unknown EGFR mutation status. Cerebellum and brain stem metastases were observed 2 years later. WBRT (40 Gy/20 f) was used and gefitinib was still taken. S1 radiotherapy was performed in October 2015 because of serious pain in her waist. In October 2016 the patient developed unbearable headaches, nausea, vomiting, and diplopia in the left eye. The cranial contrast-enhanced magnetic resonance imaging (MRI) showed hydrocephalus with associated meningeal enhancement (Figure 1A). Lumbar puncture examination of CSF revealed a small number of nuclear cells but no tumor cells. NGS results of the CSF sample is EGFR 19del without T790M. Then, erlotinib (150 mg/day) orally and intravenous infusion nimotuzumab (200 mg/m²) once a week were performed. During the first 7 days, a corresponding improvement in the symptoms of headache and vomiting was found. A repeated cranial contrast-enhanced MRI at 1 month of posttreatment follow-up showed a decrease in size, range and degree of LM loci in her brain stem and cerebellum (Figure 1B). After 6 weeks, nimotuzumab was discontinued while erlotinib was maintained. After 2 months, her symptoms were resolved and she was discharged from hospital and continued to take erlotinib (150 mg/day) orally.

Case 2
In February 2015, a 44-year-old female was diagnosed with adenocarcinoma of the upper left lobe of lung with bone metastasis. DNA sequencing of her tumor specimen obtained before treatment revealed a EGFR mutation (exon 19 deletion). Thus she was treated with gefitinib (250 mg/day) orally. In January 2017, she had disease progression with enlargement of skin nodules in the left parietal thus surgery was required. After surgery, contrast-enhanced MRI of her head demonstrated evidence of progressive intracranial metastasis (Figure 2A). A tissue sample test showed there was T790M by ARMS. However, the patient refused to take osimertinib due to economic problems. WBRT (40 Gy/20 f) was used and the patient started to take erlotinib. After 4 months, the metastases in her brain had gone (Figure 2B). In February 2019, she presented with double vision, facial twitching, and loss of hearing. A contrast-enhanced MRI of the brain showed progressive intracranial metastases with new leptomeningeal involvement (Figure 2C). The patient started to take erlotinib (150 mg/day) orally plus intravenous infusion nimotuzumab (200 mg/m²) once a week for 6 weeks. After 2 weeks, a repeated cranial contrast-enhanced MRI showed a remarkable shrinkage of LM (Figure 2D). One month later, an obvious improvement was shown on another repeated cranial contrast-enhanced MRI of her head (Figure 2E). The patient was discharged from hospital and continued to take erlotinib (150 mg/day) orally.

Case 3
A 78-year-old female, PET-CT showed some lumps in the right upper lobe of lung and some loci in thoracic and lumbar vertebra with abnormally high carcinoembryonic antigen (CEA). Since she declined bronchoscopy and percutaneous lung puncture, she was highly suspected as lung cancer with thoracic and lumbar vertebra metastases. DNA sequencing of her blood specimen obtained revealed a EGFR mutation (exon 19 deletion), in addition, her demographic profile is listed in Table 1. Therefore, she initiated standard dosing of erlotinib (150 mg) and achieved partial response for 1 year. In May 2015, a radiotherapy in T4 (34 Gy/17 f) was initiated and erlotinib was still being taken. In December 2015, her clinical course was complicated by involuntary jitter of limbs, and word-finding difficulty. A brain contrast-enhanced MRI showed likelihood of

For personal use only.

Table 1

<table>
<thead>
<tr>
<th>Case</th>
<th>Demographic profile</th>
<th>EGFR mutation</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A 45-year-old female,</td>
<td>EGFR 19del</td>
<td>Gefitinib, S1 radiation</td>
<td>Good improvement</td>
</tr>
<tr>
<td>2</td>
<td>A 44-year-old female,</td>
<td>EGFR 19del</td>
<td>Gefitinib, WBRT, Erlotinib</td>
<td>Good improvement</td>
</tr>
<tr>
<td>3</td>
<td>A 78-year-old female,</td>
<td>EGFR 19del</td>
<td>Erlotinib, Radiotherapy</td>
<td>Partial response</td>
</tr>
</tbody>
</table>

OncoTargets and Therapy 2020:13
The three patients in this study were all previously treated with chemotherapy and radiation therapy, however, their condition continued to deteriorate. It has been reported that EGFR-TKIs were effective for treating patients with LM harboring EGFR-sensitive mutation. Gefitinib and erlotinib are small-molecule, first-generation EGFR-TKIs. Studies have shown that the percentage of erlotinib penetrating the CSF is 2–3%. Porta et al retrospectively identified the efficacy of erlotinib in 17 brain metastases patients with EGFR mutations, with a median progression-free survival (PFS) of 11.7 months. A Phase II prospective study showed that the objective response rate (ORR), median PFS and overall survival (OS) of brain metastasis patients with EGFR mutations treated with erlotinib were 83%, 6.6 months, and 15.9 months, respectively. However, conventional doses of erlotinib have a moderate effect on the control of brain metastasis, and some scholars have proposed high-dose pulse administration. A phase II study showed that the ORR was 74% and median PFS was 10 months with brain metastasis patients taking pulse-continuous dose erlotinib. However, high-dosage of erlotinib will cause more serious side effects and economic effects, so it is not widely used in clinical practice. In our cases, two of the patients were treated with gefitinib at an earlier stage. Compared with gefitinib, the serum concentrations of erlotinib were relatively high. We speculated that erlotinib, instead of high-dose of gefitinib, may be also effective for the treatment of LM. In these cases, we used erlotinib (150 mg/d) for the treatment of patients with EGFR mutant or gefitinib-refractory NSCLC with LM and good efficacy with minor side effects were achieved.

For the second generation of EGFR-TKIs, afatinib is the main representative, there were no significant differences between it and the first generation EGFR-TKIs in the study results of LUX-lung 7. In another trial, after the progression of chemotherapy and first-generation EGFR-TKI treatment in 100 patients with NSCLC, non-small lung cancer; LM, Leptomeningeal metastasis; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors; PFS, progression free survival; WBRT, whole-brain radiotherapy.

| Table 1 Patient Baseline Characteristics and Treatment Regimens |
|----------------|----------------|----------------|
| Index | Patient 1 | Patient 2 | Patient 3 |
| Age (years) | 45 | 44 | 48 |
| Gender | Female | Female | Female |
| Smoking status | Non-smoker | Non-smoker | Non-smoker |
| Pathologic type | Adenocarcinoma | Adenocarcinoma | NSCLC |
| EGFR | Not tested | Positive | Not tested |
| Previous TKI therapies | Gefitinib | Gefitinib and erlotinib | Erlotinib |
| TKI PFS | 2 years | Nearly 2 years and 1 year | 29 months |
| WBRT before LM | Yes | Yes | No |
| WBRT after LM | Yes (uncompleted) | No | Yes |
| Previous therapies, n | 4 | 6 | 1 |
| Type | Gemcitabine | Gefitinib | Erlotinib |
| Type | Gefitinib | Carboplatin | |
| WBRT | Paclitaxel | | |
| L5 and S1 radiotherapy | Radiotherapy in surgical scar | | |
| Carboplatin | Erlotinib | | |
| Pemtrexed | Pemtrexed | | |
| cisplatin | | | |
| γ knife and WBRT | | | |
| Pemtrexed | | | |
| Bevacizumab | | | |
| Temozolomide | | | |
| L3 and cerebellum radiotherapy | | | |

**Abbreviations:** NSCLC, non-small lung cancer; LM, Leptomeningeal metastasis; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors; PFS, progression free survival; WBRT, whole-brain radiotherapy.

leptomeningeal and parenchyma metastases in her brain (Figure 3A). DNA sequencing of her blood specimen obtained revealed a EGFR mutation (exon 19 deletion) without T790M. The patient then began treatment with the combination of erlotinib (150 mg/day) orally plus intravenous infusion nimotuzumab (200 mg/m²) weekly for 6 weeks. After 1 week, the patient’s condition continued to deteriorate. Considering these observations, WBRT was performed with patient consent in the hope of damaging BBB function to increase the level of CSF erlotinib. One month later (Figure 3B), the patient noted a concomitant improvement in her symptoms of tremor. Her lower limbs strength and memory improved, and she was able to return to work and continued to take erlotinib (150 mg/day) orally.

**Discussion**

Historically, median survival from the diagnosis of LM was 46 weeks if left untreated or treated for 23 months. Chemotherapy and radiation therapy are the main methods to treat NSCLC patients with LM. The three patients in this study were all previously treated with chemotherapy and radiation therapy, however, their condition continued to deteriorate.

It has been reported that EGFR-TKIs were effective for treating patients with LM harboring EGFR-sensitive mutation. Gefitinib and erlotinib are small-molecule, first-generation EGFR-TKIs. Studies have shown that the percentage of erlotinib penetrating the CSF is 2–3%. Porta et al retrospectively identified the efficacy of erlotinib in 17 brain metastases patients with EGFR mutations, with a median progression-free survival (PFS) of 11.7 months. A Phase II prospective study showed that the objective response rate (ORR), median PFS and overall survival (OS) of brain metastasis patients with EGFR mutations treated with erlotinib were 83%, 6.6 months, and 15.9 months, respectively. However, conventional doses of erlotinib have a moderate effect on the control of brain metastasis, and some scholars have proposed high-dose pulse administration. A phase II study showed that the ORR was 74% and median PFS was 10 months with brain metastasis patients taking pulse-continuous dose erlotinib. However, high-dosage of erlotinib will cause more serious side effects and economic effects, so it is not widely used in clinical practice. In our cases, two of the patients were treated with gefitinib at an earlier stage. Compared with gefitinib, the serum concentrations of erlotinib were relatively high. We speculated that erlotinib, instead of high-dose of gefitinib, may be also effective for the treatment of LM. In these cases, we used erlotinib (150 mg/d) for the treatment of patients with EGFR mutant or gefitinib-refractory NSCLC with LM and good efficacy with minor side effects were achieved.

For the second generation of EGFR-TKIs, afatinib is the main representative, there were no significant differences between it and the first generation EGFR-TKIs in the study results of LUX-lung 7. In another trial, after the progression of chemotherapy and first-generation EGFR-TKI treatment in 100 patients with
LM, the median time to progression with afatinib was 3.6 months, and the results were similar to those patients without LM. In our case, we did not switch to afatinib after gefitinib failed.

In the clinical setting, mutations during therapy lead to acquired EGFR-TKI resistance. For example, T790M substitution in EGFR exon 20 has been reported in approximately 60% of cases with acquired resistance to EGFR-TKIs. Under this context, osimertinib, the third generation of EGFR-TKIs, emerged. In the AURA 3 subgroup analysis, compared with chemotherapy, the median PFS of 144 patients with T790M and brain metastasis treated with osimertinib prolonged for 4 months (8.5 M vs 4.2 M), ORR 54% and CR 12%. However, in the FLAURA trial, brain metastases occurred in 21% of the 556 patients, the median PFS of patients treated with osimertinib was 15.2 months (15.2 vs 9.6 months) compared with first-generation EGFR-TKIs. Resistance progression of first-generation EGFR occurred in all three cases in this study. Furthermore, resistance progression in this study was local progress. According to the latest NCCN guidelines, patients with local progression can follow the original regimen with local treatment. However, osimertinib is only authorized in patients with EGFR T790M, so we did not choose to switch to osimertinib immediately after resistance without EGFR T790M.

AZD 3759 is an oral TKI developed for brain metastasis, the ratio of unbound brain to plasma concentration was as high as 0.65. In the BLOOM study, intracranial ORR and

Figure 1 Contrast enhanced MRI of a 45-year-old female with adenocarcinoma: (A) contrast enhanced MRI showing leptomeningeal metastases loci in her cerebellum; (B) contrast enhanced MRI showing leptomeningeal metastases loci in her cerebellum decreased after 1 month treatment of nimotuzumab combined with erlotinib. The LM lesions were pointed by the arrows.
Figure 2 Contrast enhanced MRI of a 44-year-old female with adenocarcinoma harboring EGFR 19 exon deletion: (A) contrast enhanced MRI showing multiple brain metastases; (B) contrast enhanced MRI showing the metastases in her brain had diminished after 4 months of erlotinib 150 mg/d orally; (C) contrast enhanced MRI showing progressive intracranial metastases with new leptomeningeal involvement after less than 1 year; (D) contrast enhanced MRI showing leptomeningeal metastases loci in her cerebellum decreased in size and range after treatment of nimotuzumab combined with erlotinib for 1 week; (E) contrast enhanced MRI showing an obvious improvement had seen in her brain 1 month later. The LM lesions were pointed by the arrows.
extracranial ORR of 38 patients with EGFR mutation and NSCLC metastasis to brain/perichondrial were 63% and 50% respectively. But further clinical studies are needed to confirm its efficacy and safety. Tesevatinib is an oral reversible TKI. The Phase 2 study is being conducted in patients who have progressed with brain metastases and/or symptomatic leptomeningeal metastases while on prior therapy with other EGFR inhibitors. Four of those five patients, CNS lesions were controlled. One enrolled patient with no prior treatment who presented with brain metastases showed a robust partial response in brain metastases in an MRI taken on Study Day 29 and showed a partial response in both brain metastases and peripheral disease at Study Day 57. Preliminary trials have shown some intracranial and extracranial efficacy, but the evidence is still insufficient.

Radiotherapy could further aggravate the edema of normal brain tissue and aggravate intracranial hypertension and is not the preferred choice for LM. However, it can be tried as a complementary method. Radiotherapy can selectively open the BBB of the target area and protect the BBB of normal tissue from damage. Therefore, the concentration of TKI and macromolecular monoclonal antibody in the cerebrospinal fluid is significantly increased, thereby improving the efficiency of anti-tumor. As shown in case 1 and case 3, the shrinkage of the LM lesions was observed after the additional radiotherapy when the condition of the patients deteriorated after the combination therapy. The curative effect of a single drug on LM is limited and appropriate combination drugs can achieve a synergistic effect, such as radiotherapy. In addition, first-line meta-analysis summarized 15 clinical trials and concluded that radiotherapy combined with EGFR-TKI for the treatment of intracranial, median PFS was superior to TKI alone or radiotherapy alone, and significantly improved OS and PFS of intracranial and extracranial, but the rash also increased. Stereotactic radiosurgery (SRS) combined with TKI has also achieved considerable efficacy. A retrospective study analyzed 222 patients with EGFR-mutated NSCLC, and concluded that OS of SRS early treatment was up to 64 months, while OS of erlotinib was only 26 months. In our case, all patients received whole-brain radiotherapy, and meningeal metastasis occurred again after whole-brain radiotherapy, so re-radiotherapy was no longer suitable.

Figure 3 Contrast enhanced MRI of a 48-year-old female with NSCLC (A) contrast enhanced MRI showing leptomeningeal and parenchyma metastases in her brain; (B) contrast enhanced MRI showing the metastases in her brain had decreased in size and range after 1 month of treatment with nimotuzumab combined with erlotinib. The LM lesions were pointed by the arrows.
In a retrospective trial, 109 cases with EGFR-mutated NSCLC with brain metastases were treated with EGFR-TKI combined with bevacizumab while the other cases used EGFR-TKI only. After treatment, the median PFS in the study was 14.4 vs 9.9 months and the intracranial PFS was 14.0 vs 8.2 months, which initially showed some efficacy. However, whether the fact that bevacizumab can cause intracranial hemorrhage or not remains unclear and bevacizumab is only used in non-squamous NSCLC. Thus, more RCT clinical data are still needed. Because of the safety of bevacizumab and the high PS score of the patients, we did not choose erlotinib combined with bevacizumab to control LM. PD-1 inhibitor combined with EGFR-TKI is not ideal for treatment, so it is not recommended. There are few reports on dual targeting therapy for central metastasis of lung cancer. In 2014, Lin et al, in the journal Lung Cancer, proposed that afatinib combined with cetuximab had good activity and tolerance in advanced non-small-cell lung cancer with leptomeningeal metastases. It has been reported that double-targeting (afatinib combined with cetuximab) can overcome acquired resistance to gefitinib in NSCLC with EGFR T790M mutation. Those evidences strongly support our use of dual-targeted therapy. Previous studies showed nivolumab had a good effect in glioma. However, the normal blood-brain barrier (BBB) will prevent nivolumab (MW: 150,000) from transmitting to brain lesions. The integrity of BBB of tumor patients or patients treated with radiation is impaired. Nivolumab may cross the BBB of these patients. In addition, erlotinib, as small-molecule and first-generation EGFR-TKIs, has a higher rate (2–3%) of penetrating the CSF. The treatment of brain/meningeal metastases of non-small cell lung cancer with erlotinib is widely accepted. However, high-dosage of erlotinib will cause more serious side effects and economic effects. Therefore, we attempted to use erlotinib which had the highest concentration of cerebrospinal fluid, erlotinib combining with nivolumab to overcome drug resistance when the meningeal lesions were more serious.

Nimotuzumab (h-R3) is a humanized IgG1 monoclonal antibody generated against the extracellular domain of EGFR purified from human placenta. Its activity is similar to that of cetuximab. Several studies have shown that nimotuzumab is effective for NSCLC. The expression rate of EGFR is 40–80% which provides a theoretical basis for the treatment of lung cancer with nimotuzumab in NSCLC. A study from Japan has shown nimotuzumab improved the antitumor effect of radiation in certain human NSCLC cell lines in vitro and nude mice in vivo. The superiority of combining EGFR targeting with the tyrosine kinase inhibitor gefitinib and monoclonal antibody cetuximab has been approved. Patients with NSCLC treated with nimotuzumab combined with methotrexate (MTX) had prolonged OS over 1 year with minimal adverse effects. Qi et al found that PFS was significantly prolonged by 1 month in the group treated with nimotuzumab compared with those without. Additionally, in a phase Ib/II study, combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraged antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. However, Kim et al found that the dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone in patients with advanced NSCLC. Over expression of the EGFR is associated with 90% of NSCLC patients, we believe the collaborative effect of nimotuzumab plus erlotinib in NSCLC patients with LM may achieve good response. Therefore, we speculated that, with the highest concentration of cerebrospinal fluid, erlotinib combining with nimotuzumab may overcome the resistance of the first generation of EGFR-TKI. For the first time, we choose erlotinib (150 mg/day) plus nimotuzumab (200 mg/m²) weekly to treat patients with EGFR mutant or gefitinib-refractory NSCLC with LM, and good efficacy was achieved. When patients were treated with nimotuzumab combined with erlotinib, their symptoms of headache, vomiting, double vision, hearing loss, tremor of limbs, strength and memory improved. Our case indicates the potential of dual targeted therapy against EGFR in treating LMC in EGFR-positive NSCLC patients who still progressed after high-dose TKI.

Conclusion
In conclusion, combination therapy of erlotinib with nimotuzumab was a promising treatment for patients with NSCLC with LM because it can provide good tolerance and incredible efficacy. However, further study with a larger number of samples is warranted.

Ethics Approval and Consent to Participate
The Ethics Committee of the General Hospital of Western Theater Command approved the study (No. 2019ky57). All participants signed an approved informed-consent form. We also obtained consent to publication of their medical data.
Funding
This work was supported by Youth Innovation Fund of General Hospital of Western Theater of command [No: 14732C119].

Disclosure
The authors report no conflicts of interest in this work.

References


